Risk Factors
for Cholangiocarcinoma: Aspirin - use and the Risk of Cholangiocarcinoma, Hepatology (2016).
It is also a significant risk factor
for Cholangiocarcinoma (CCA) or bile duct cancer.
«In 3 out of the 6 patients we analyzed, we found compelling, treatable and unexpected genetic alterations that would never have been found by normal testing methods
for cholangiocarcinoma,» says Mitesh Borad, M.D., a Mayo Clinic oncologist and lead author of the paper.
Not exact matches
«We now hope to design larger clinical studies to treat patients» tumors harboring these novel genomic aberrations to further explore the precise extent of clinical benefit
for patients with primary or advanced
cholangiocarcinoma.»
Physicians at Mayo Clinic's Individualized Medicine Clinic and researchers at the Translational Genomics Research Institute (TGen) have personalized drug treatments
for patients with
cholangiocarcinoma using genomic sequencing technologies.
A Role
for Focal Adhesion Kinase Signaling in Tumor Necrosis Factor - α — Dependent Matrix Metalloproteinase - 9 Production in a
Cholangiocarcinoma Cell Line, CCKS1